The challenges of tumor genetic diversity

Cancer

Volumn 123, Issue 6, 2017, Pages 917-927

  Mroz, Edmund A ^a   Rocco, James W ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

driver mutations; immunotherapy; intratumor heterogeneity; next generation sequencing; targeted therapy

Indexed keywords

B RAF KINASE; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TUMOR MARKER;

CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COPY NUMBER VARIATION; GENE LOCUS; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; MOLECULAR EVOLUTION; NEXT GENERATION SEQUENCING; NONHUMAN; PERSONALIZED MEDICINE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; REVIEW; TUMOR GENE; ANIMAL; CLONAL EVOLUTION; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; NEOPLASMS; PATHOLOGY; PROGNOSIS;

ANIMALS; BIOMARKERS, TUMOR; CLONAL EVOLUTION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PRECISION MEDICINE; PROGNOSIS;

EID: 84999017192     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30430     Document Type: Review

References (76)

1. The Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113–1120.
2. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501:338–345.
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–1558.
4. Sawyers C. Targeted cancer therapy. Nature. 2004;432:294–297.
5. Haber DA, Bell DW, Sordella R, et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol. 2005;70:419–426.
6. Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014;35:41–50.
7. Leiserson MD, Vandin F, Wu HT, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet. 2015;47:106–114.
8. Kaye SB. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years. Ann Oncol. 2016;27(suppl 1):i1–i3.
9. Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects [serial online]. BMC Med. 2015;13:188.
10. Iorio F, Knijnenburg Theo A, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166:740–754.
11. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231–1241.
12. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140–156.
13. Pon JR, Marra MA. Driver and passenger mutations in cancer. Annu Rev Pathol. 2015;10:25–50.
14. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218.
15. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal [serial online]. Sci Signal. 2013;6:pl1.
16. ECOG-ACRIN Cancer Res. Group. NCI-MATCH/EAY131 Interim Analysis—ECOG-ACRIN. Philadelphia, PA: ECOG-ACRIN Cancer Res. Group; 2016. Available at: http://ecog-acrin.org/nci-match-eay131/interim-analysis. Accessed October 21, 2016.
17. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12:323–334.
18. Mazor T, Pankov A, Song JS, Costello JF. Intratumoral heterogeneity of the epigenome. Cancer Cell. 2016;29:440–451.
19. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–28.
20. Loeb LA, Springgate CF, Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res. 1974;34:2311–2321.
21. Bozic I, Gerold JM, Nowak MA. Quantifying clonal and subclonal passenger mutations in cancer evolution [serial online]. PLoS Comput Biol. 2016 12:e1004731.
22. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees [serial online]. Sci Transl Med. 2012;4:127ps110.
23. Hakansson L, Trope C. On the presence within tumours of clones that differ in sensitivity to cytostatic drugs. Acta Pathol Microbiol Scand A. 1974;82:35–40.
24. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science. 1977;197:893–895.
25. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978;38:3174–3181.
26. Heppner GH. Tumor heterogeneity. Cancer Res. 1984;44:2259–2265.
27. Metzker ML. Sequencing technologies—the next generation. Nat Rev Genet. 2010;11:31–46.
28. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet. 2008;9:387–402.
29. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–892.
30. Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30:413–421.
31. Raphael BJ, Dobson JR, Oesper L, Vandin F. Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine [serial online]. Genome Med. 2014;6:5.
32. Mroz EA, Tward AD, Hammon RJ, Ren Y, Rocco JW. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from The Cancer Genome Atlas [serial online]. PLoS Med. 2015;12:e1001786.
33. Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2013;49:211–215.
34. Hardiman KM, Ulintz PJ, Kuick RD, et al. Intra-tumor genetic heterogeneity in rectal cancer. Lab Invest. 2016;96:4–15.
35. Bruna A, Rueda OM, Greenwood W, et al. A biobank of breast cancer explants with preserved intratumor heterogeneity to screen anticancer compounds. Cell. 2016;167:260–274, e222.
36. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer. 2013;119:3034–3042.
37. Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes [serial online]. Nat Commun. 2016;7:11479.
38. Bozic I, Nowak MA. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc Natl Acad Sci U S A. 2014;111:15964–15968.
39. Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1–23.
40. Bozic I, Allen B, Nowak MA. Dynamics of targeted cancer therapy. Trends Mol Med. 2012;18:311–316.
41. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4:94–109.
42. Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy [serial online]. Elife. 2013;2:e00747.
43. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128.
44. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74.
45. McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463–1469.
46. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–829.
47. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
48. National Cancer Institute. Exceptional-Responders-Q-and-A. Bethesda, MD: National Cancer Institute; 2014. Available from URL: http://www.cancer.gov/news-events/press-releases/2014/ExceptionalRespondersQandA. Accessed October 21, 2016.
49. Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer after 3-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer. 1985;55:1123–1128.
50. Peng H, Chen L, Zhang Y, et al. The tumour response to induction chemotherapy has prognostic value for long-term survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma [serial online]. Sci Rep. 2016;6:24835.
51. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501.
52. Morris LG, Chandramohan R, West L, et al. The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform [published online ahead of print 2016 Jul 21]. JAMA Oncol. doi: 10.1001/jamaoncol.2016.1790.
53. Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479–491.
54. Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacol Ther. 2016;157:120–124.
55. Mertes F, Elsharawy A, Sauer S, et al. Targeted enrichment of genomic DNA regions for next-generation sequencing. Brief Funct Genomics. 2011;10:374–386.
56. Coonrod EM, Margraf RL, Voelkerding KV. Translating exome sequencing from research to clinical diagnostics. Clin Chem Lab Med. 2012;50:1161–1168.
57. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012;2:82–93.
58. Foundation Medicine Inc. Technical Information and Test Overview. Cambridge, MA: Foundation Medicine Inc; 2014. Available at: http://foundationone.com/ONE-I-001-20140804_(nobleed)TechnicalSpecs.pdf. Accessed October 21, 2016.
59. Ledgerwood LG, Kumar D, Eterovic AK, et al. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget. 2016;7:27185–27198.
60. Chung CH, Guthrie VB, Masica DL, et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol. 2015;26:1216–1223.
61. National Institutes of Health. Newly launched Genomic Data Commons to facilitate data and clinical information sharing. Bethesda, MD: National Institutes of Health; 2016. Available at: http://cancergenome.nih.gov/newsevents/newsannouncements/genomic-data-commons-launch. Accessed October 21, 2016.
62. National Cancer Institute. Expansion of data in the GDC-National Cancer Institute. Bethesda, MD: National Cancer Institute; 2016. Available at: http://www.cancer.gov/news-events/press-releases/2016/gdc-data-expansion-fmi?cid=eb_govdel. Accessed October 21, 2016.
63. National Cancer Institute. Mutation Annotation Format (MAF) Specification-TCGA-National Cancer Institute-Confluence Wiki. Bethesda, MD: National Cancer Institute; 2014. Available at: https://wiki.nci.nih.gov/display/TCGA/Mutation+Annotation+Format+%28MAF%29+Specification. Accessed October 21, 2016.
64. Oncology Research Information Exchange Network (ORIEN). Oncology Research Information Exchange Network. Tampa, FL: ORIEN; 2016. Available at: http://oriencancer.org/. Accessed October 21, 2016.
65. The Cancer Genome Atlas (TCGA). Importance of Tissue Samples—TCGA. Bethesda, MD: TCGA, National Human Genome Research Institute, National Cancer Institute, National Institutes of Health; 2016. Available at: http://cancergenome.nih.gov/cancergenomics/tissuesamples. Accessed October 21, 2016.
66. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–688.
67. Murphy M, Alavi K, Maykel J. Working with existing databases. Clin Colon Rectal Surg. 2013;26:5–11.
68. National Cancer Institute. Submit Data/NCI Genomic Data Commons. Bethesda, MD: National Cancer Institute; 2016. Available at: https://gdc.nci.nih.gov/submit-data. Accessed October 21, 2016.
69. National Cancer Institute. Viewer-GDC Docs. Bethesda, MD: National Cancer Institute; 2016. Available at: https://gdc-docs.nci.nih.gov/Data_Dictionary/viewer/?view=table-definition-view&id=treatment. Accessed October 21, 2016.
70. National Institutes of Health (NIH). NIH Launches Comprehensive Effort to Explore Cancer Genomics-TCGA. Bethesda, MD: National Institutes of Health; 2005. Available at: http://cancergenome.nih.gov/newsevents/newsannouncements/news_12_13_2005. Accessed October 21, 2016.
71. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 1999;9:M57–M60.
72. Venkatesan S, Swanton C. Tumor evolutionary principles: how intratumor heterogeneity influences cancer treatment and outcome. Am Soc Clin Oncol Educ Book. 2016;35:e141–e149.
73. Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 2014;4:166–174.
74. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46:225–233.
75. Waclaw B, Bozic I, Pittman ME, Hruban RH, Vogelstein B, Nowak MA. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature. 2015;525:261–264.
76. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 2014;514:54–58.